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Background: Tacrolimus (TAC) is an immunosuppressant used in organ transplant recipients. It is a sub-
strate of drug transporter ABCB1 as well as of cytochrome P4503A (CYP3A).
Aim: To assess the influence of ABCB1 (3435 C>T) and CYP3A5 (6986 A>G) genes polymorphism of liver
transplant donors and recipients on blood level and dose requirements of oral tacrolimus, to help in
designing an individualized tacrolimus regimen for liver transplant recipients.
Subjects and methods: Forty-eight adult liver transplant recipients and their matching living donors were
prospectively enrolled in this study. TAC doses and blood concentration were recorded on 1st, 2nd and
3rd days, after 1 and 2 weeks, and at 1, 3 and 6 months postoperatively using ultra performance liquid
chromatography Tandem mass spectrometry. Genotyping of ABCB1 (3435C>T) and CYP450 3A5
(6986A>G) genes were determined by Polymerase chain reaction followed by restriction fragment length
polymorphism and by TaqMan allelic discrimination assay techniques, respectively.
Results: Of the enrolled 48 recipients, CYP3A5⁄3/⁄3 and CYP3A5⁄1/⁄3 genotypes were detected in 18
(37.5%) and in 20 (41.7%) recipients respectively, while ABCB1 CT and TT genotypes were detected
in16 (33.3%) and 10 (20.8%) recipients respectively. TAC daily dose was significantly increased among
recipients carrying ABCB1 CC genotype compared to recipients carrying CT and TT genotypes during
and after the first month postoperatively. During 1st, 2nd days and 2 weeks post-transplant, a significant
increase of TAC concentration / dose ratio was observed among recipients carrying CYP3A5⁄3⁄3 genotype
than recipients carrying 1⁄1⁄ and 1⁄3⁄ genotypes, and among recipients carrying ABCB1 CT and TT geno-
types compared to those carrying CC genotype on 1st, 3rd days and at 3 months postoperatively.
Conclusions: ABCB1 and CYP3A5 genetic polymorphism is one of the factors influencing TAC pharmacoki-
netics, screening for these SNPs prior to liver transplantation might be helpful for individualization of
tacrolimus treatment.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Liver transplantation (LT) is the only effective radical cure for all
types of end stage liver diseases and provides new hope for end
stage liver disease patients. Immunosuppressant is the main pre-
ventive and treatment measure for organ transplant rejections.
The appropriate use of immunosuppressant is directly related to
the survival of the liver transplant recipients [1].Tacrolimus (TAC) is the backbone of immunosuppressive drugs
used worldwide in organ transplantation, and characterized by a
narrow therapeutic range and high inter-individual variability in
its pharmacokinetics [2]. Over the years, TAC has become well
established as the primary immunosuppressant employed by most
liver transplant centers. It was proven to be valuable with better
graft and patient survival rates post liver transplantation [3]. Ther-
apeutic drug monitoring of TAC in blood is necessary to provide an
effective immunosuppression and avoid adverse effects after organ
transplantation [4].
Tacrolimus is a metabolic substrate for (CYP450) 3A enzymes –
in particular CYP3A5 and is transported out of cells via
P-glycoprotein which is the product of ABCB1 gene [5].
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the pharmacokinetics of tacrolimus and the polymorphisms of the
CYP3A5 and ABCB1 genes [5]. Tacrolimus has poor bioavailability
after oral administration (25%; range, 4–93%) and is extensively
metabolized by the cytochrome P4503A (CYP3A) oxidative
enzymes CYP3A4 and CYP3A5 in the liver and small intestine [6].
A single nucleotide polymorphism (SNP) in the CYP3A5 gene
involving an adenine (A) to guanine (G) transition at position
6986 within intron 3 was found to be strongly associated with
CYP3A5 protein expression. At least one CYP3A5⁄1 allele was found
to express large amounts of CYP3A5 protein, whereas homozygous
for the CYP3A5⁄3 allele did not express significant quantities of
CYP3A5 protein, as it causes alternative splicing and results in a
truncated protein (which is not functional) and a severe decrease
of functional CYP3A5 [4].
TAC is also a substrate of P-glycoprotein (P-gp), one of the ATP-
binding cassette transporters that actively transport its substrates
out of cells by the driving force of ATP [7]. P-gp is encoded by the
multi-drug resistance (MDR1) gene, also known as ABCB1 [8].
Physiologically, P-gp is present in the small intestine, liver, kidney,
adrenal gland and pancreas [9]. Efflux activity associated with P-
gp, therefore, reduces the intestinal absorption of orally adminis-
tered drugs while enhancing their biliary excretion through the
liver and tubular excretion in the kidney [10]. Substitution of cyto-
sine (C) by thymine (T) in the ABCB1 3435 gene in exon 26 is con-
nected with the change of expression and activity of P-gp. It was
observed that patients with genotype of ABCB1 343CC (homozy-
gote CC) showed an expression of P-gp in the duodenum endothe-
lium two times higher compared to individuals with ABCB1 343TT
genotype (homozygote TT). However, the intermediate values of P-
gp activity and expression were noted in patients with ABCB1
3435CT genotype (heterozygote CT) compared to both homozygote
groups [11].
The aim of this pilot study is to assess the influence of ABCB1
(3435 C>T) and CYP3A5 (6986 A>G) genes polymorphisms of both
donors and recipients of liver transplant on blood level and dose
requirements of oral tacrolimus, in an attempt to help in designing
an individualized tacrolimus regimen for Egyptian liver transplant
recipients.2. Subjects and methods
This study was carried out according to the Code of Ethics of the
World Medical Association (Declaration of Helsinki) for experi-
ments in humans. Fifty consecutive adult LT recipients and their
living donors were prospectively included in the study (two
patients died during the first two weeks post transplantation and
were excluded from the study). Recipients underwent graft LT at
National Liver Institute (NLI), Menoufia University in the period
from January 2011 to July 2014; they were 44 males and 4 females
with age ranged from 24 to 51 years. Their donors were 27 males
and 21 females with age ranged from 21 to 40 years. The study
protocol was approved by the ethics committees of the NLI and
Faculty of Medicine, Menoufia University. A written informed
consent was taken from all subjects prior to enrollment in this
study. Patients were followed up in the Liver Transplantation
Unit, NLI during the first postoperative month then in the
Hepatology Department till the end of the sixth month (endpoint
of the study).
Adult recipients were included if they were given TAC-based
immunosuppressive regimen for 6 months. They were excluded if
they received any immunosuppressive regimen during the first
six months other than TAC, had acute rejection, graft failure or sev-
ere post-LT complications necessitating TAC dose modification as
severe infections.Please cite this article in press as: Helal M et al. Egypt J Med Hum Genet (201Recipients’ body weights were recorded and laboratory investi-
gations including blood glucose level, total and direct bilirubin,
urea and creatinine were done preoperatively and 1, 3 and
6 months postoperatively, using the Autoanalyzer SYNCHRON
CX9ALX (Beckman Coulter Inc., CA, USA).
After transplantation, the recipients were given TAC orally from
the first day post-operative. The dose was subsequently adjusted
according to the whole blood trough levels where the target trough
level was 10–15 ng/ml in the first 4 weeks then 5–10 ng/ml till the
end of follow-up according to the followed treatment protocol at
NLI.
2.1. Therapeutic drug monitoring of tacrolimus (TDM)
Daily weight adjusted dose of TAC was recorded, the dose was
0.05–0.14 mg/kg/day divided into 2 doses during the first month,
was 0.06–0.142 mg/kg/day after the first month and it was 0.08–
0.19 mg/kg/day at 3 and 6 months. Measurement of whole blood
TAC trough concentration (ng/ml) on 1st, 2nd and 3rd days, after
1 and 2 weeks, and at 1, 3 and 6 months post-operative using ultra
performance liquid chromatography tandem mass spectrometry
(LC/MS/MS analysis) (ACQUITY UPLC H-Class. Waters Corporation,
MA, USA). Whole blood samples were taken at 9 am, 2 h before the
next TAC dose. Concentration/dose (C/D) ratio was calculated by
dividing TAC trough blood concentration by the corresponding
weight adjusted daily dose (mg/kg/day).
2.2. ABCB1 and CYP genes genotyping
Five ml of venous blood were withdrawn from the recipients
and their donors, preserved in Ethylenediaminetetraacetic acid
(EDTA) containing tubes and stored at -80 C for genotyping.
DNA was extracted from frozen EDTA treated blood sample using
Gene JETTM Whole Blood Genomic DNA Purification Mini Kit
(Thermo Fisher Scientific, Inc. EU/Lithuania).
(A) Genotyping of CYP450 3A5 (6986A>G, rs776746) by TaqMan
allelic discrimination assay technique: The presence of two primer/
probe pairs in each reaction allows genotyping of the two possible
variants of a single nucleic acid sequence at the SNP site in a target
template sequence. The Allelic Discrimination assay classifies
unknown samples as: homozygotes (samples having only allele 1
or allele 3) and heterozygotes (samples having both allele 1 and
allele 3).
The primers were: forward (50-CATCAGTTAGATGACAGATGA-3)
and reverse (50-GGTCCAAACAGGGAAGAAATA-3) (Bioneer, Inc.
USA). Probes were: Allele 1 (50-FAM-GGTGGCTGGGCCGGGGCTGT
CCAGT-BHQ-30) and Allele 3 (50-HEX GGTCCAAACAGGGAA
GAAATA-BHQ-30) (Bioneer, Inc. USA) [12]. PCR amplification of
CYP3A5 was carried out to a total volume of 25 ll, containing
5 ll (0.1 lg/ll) of genomic DNA template, 12.5 ll Maxima probe
Master Mix (2X) (Thermo scientific), composed of Maxima Hot
Start Taq DNA polymerase and dNTPs in an optimized PCR buffer,
0.3 ll (30 pmol) of each primer, 1.2 ll (12 pmol) of each probe
and 4.5 ll of nuclease-free water. Amplification of DNA product
was performed by pre-programmed thermal cycler LINE GENE
9660 (BIOER Technology, Co.,LTD, JAPAN), the PCR cycling condi-
tions were initial denaturation for 10 min at 95 C, followed by
50 cycles with denaturation of 15 sec at 92 C and 60 s at 60 C
for annealing and extension.
(B) Genotyping of ABCB1 gene (3435C>T, rs1045642) by poly-
merase chain reaction-restriction fragment length polymorphism
(PCR-RFLP): Amplification of DNA product was performed by pre-
programmed thermal cycler (Techne, E.U.) using the following pri-
mers (Metabion International, Germany): Forward: 50-GATCTGT
GAACTCTTGTTTTCA-3; Reverse: 50-GAAGAGAGACTTACATTAGGC-
3 [12].6), http://dx.doi.org/10.1016/j.ejmhg.2016.10.005
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to a total volume of 26.5 ll, containing approximately 100 ng of
genomic DNA (10 ll), 0.5 ll of each 100 pmol/L primers, 12.5 ll
of Dream Taq green PCR master mix (2X) (Fermentas, Life Science,
E.U.) (containing dream Taq DNA polymerase in 2X Dream Taq
green buffer, dATP, dCTP, dGTP, dTTP, 0.4 mM each and 4 mM
MgCl2) and 3 ll sterile H2O. Reaction conditions included initial
denaturation at 95 C for 10 min, followed by 40 cycles, 30 s at
94 C, 30 s at 54 C, and 45 s at 72 C, then a final extension at
72 C for 5 min. PCR product (244 bp) was digested with the
restriction enzyme MboI fast-digest (Fermentas, Life Science, E.
U.). 10 ll PCR product, 2 ll 10 buffer, 7 ll nuclease-free water,
1 ll MboI -fast digest, were mixed gently and incubated at 37 C
for 30 min. The reaction mixture was electrophoresed through 3%
agarose gel stained with ethidium bromide, 25 bp gene ruler
DNA ladder (Thermo Scientific Inc, USA) was used. Fragments of
DNA were photographed under ultraviolet transillumination (Syn-
gene, Bioimaging, Ingenius, Canada). Fragments from patients who
were homozygous for the SNP (TT) 3435 C>T were uncut and
showed a single band at 244 bp and 4 (not seen). Fragments from
heterozygotes (CT) were partially digested and showed three
bands at 244 bp, 172 bp and 68 bp. Fragments of the wild type
allele C were digested and showed two bands that are 172 bp,
68,bp and 4 (not seen) [13].
2.3. Statistical analysis
Results were collected, tabulated, statistically analyzed by IBM
personal computer and statistical package SPSS, version 19.0
(IBM Corp, Armonk, NY, USA). The current study showed normal
distribution of allelic variants of both ABCB1 and CYP3A5 genes
according to Hardy Weinberg test of equilibrium.Distribution of CYP3A5 and ABCB1 genotypes in liver transplant recipients and
donors.
Studied
genes
Genotypes Recipients (n = 48) n (%) Donors (n = 48) n (%)
CYP3A5 ⁄1/⁄1 10 (20.8) 10 (20.8)
⁄1/⁄3 20 (41.7) 18 (37.5)
⁄3/⁄3 18 (37.5) 20 (41.7)
ABCB1 CC 22 (45.9) 22 (45.9)
CT 16 (33.3) 16 (33.3)
TT 10 (20.8) 10 (20.8)
n = number, data are presented as number and percentage.3. Results
3.1. Characteristics of study population
A total of 48 consecutive adult LT recipients and their living
donors were prospectively included in this study with mean age
of 45.8 ± 5.7 (91.7% were males), their 48 donors mean age was
28.8 ± 6.8 (56.3% of them were males). The mean age of donors is
lower than recipients as they were selected with younger age to
be fit for the operation and give better graft survival results.
3.2. Variations of tacrolimus daily dosage and concentration/dose
(C/D) ratio during the period of follow up
TAC dose was gradually increased during 6 months post trans-
plantation to reach the desired TAC trough concentration, as during
the 1st month the mean dose was 0.08 ± 0.02, and reached
0.10 ± 0.02, 0.13 ± 0.030 and 0.12 ± 0.03 after 1, 3 and 6 months
postoperative respectively, while recipients TAC C/D ratios showed
two increases during the period of follow up (during the first
2 weeks and 3rd month postoperatively), where the mean C/D
ratio of TAC on 1st, 2nd and 3rd days, after 1 and 2 weeks, and at
1, 3 and 6 months postoperative were, 61.19 ± 35.09,
74.42 ± 33.35, 75.19 ± 40.23, 100.74 ± 60.99, 106.27 ± 87.16,
82.78 ± 34.12, 109.82 ± 37.98, 91.68 ± 40.14 respectively. (Figs. 1
and 2), this wide range of tacrolimus daily dose and C/D ratio con-
firms the large inter individual variation of TAC oral bioavailability.
Frequency of CYP3A5 and ABCB1 genotypes in liver transplant
recipients and donors is displayed in Table 1 where: CYP3A5⁄3/⁄3-
genotype was detected in 18 (37.5%), CYP3A5⁄1/⁄3 in 20 (41.7%)
and CYP3A5⁄1/⁄1 in 10 (20.8%) recipients’ cases. Their donors geno-
types were CYP3A5⁄3/⁄3 genotype was detected in 20 (41.7%),Please cite this article in press as: Helal M et al. Egypt J Med Hum Genet (201CYP3A5⁄1/⁄3 in 18 (37.5%) and CYP3A5⁄1/⁄1 in 10 (20.8%) donors,
no significant difference was noticed between the two groups
(p > 0.05).3.3. For ABCB1 gene
ABCB1 CC genotype was observed in 22 (45.9%), CT in16 (33.3%)
and TT 10 (20.8%) recipients. The same distribution was identified
in their donors.3.4. Comparison between different CYP3A5 and between ABCB1
genotypes revealed that: (data are not shown)
No significant difference regarding age, gender, weight, serum
levels of bilirubin, urea and creatinine between the different geno-
types of both genes, meanwhile significant increase in random
blood sugar was observed among ABCB1 CC genotype (wild type,
rapid metabolizer) compared to other genotypes; CT and TT preop-
eratively (p = 0.008) and in non- expresser mutant CYP3A5⁄3/⁄3
genotype recipients compared to recipients carrying 1⁄/3⁄ and6), http://dx.doi.org/10.1016/j.ejmhg.2016.10.005
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(p = 0.04) respectively.
3.5. Effect of CYP3A5 and ABCB1 genes polymorphism on tacrolimus
dosage and concentration/dose (C/D) ratio in the liver transplant
recipients and donors
3.5.1. For CYP3A5 gene
Over 6 months of follow up post transplantation, TAC daily dose
among recipients carrying CYP3A5⁄3/⁄3 genotype (non-expressers)
were not significantly different from those carrying 1⁄/3⁄ and 1⁄/1⁄
genotypes (data not shown). A significant increase (p value < 0.05)
in C/D ratios was observed among recipients carrying 3⁄/3⁄ geno-
type than recipients carrying 1⁄/1⁄ and 1⁄/3⁄ genotypes during
1st, 2nd days and 2 weeks postoperatively, meanwhile no signifi-
cant difference was observed during the remaining period of follow
up. Also, higher C/D ratios (although not statistically significant)
were observed in recipients receiving graft with 3⁄/3⁄ genotype
and it reached a statistically significant level only at the end of
1st week postoperatively (p value < 0.05) compared with recipi-
ents receiving graft with 1⁄/1⁄ and 1⁄/3⁄ genotypes during the per-
iod of study (Table 2).
3.5.2. For ABCB1 gene
During and after the first month postoperatively: TAC daily dose
was significantly increased among recipients carrying CC genotype
(high activity) compared to recipients carrying CT and TT geno-
types (data not shown). A significant increase in C/D ratio was
detected among recipients carrying CT and TT genotypes compared
to those carrying CC genotype (high activity) during the whole per-
iod of follow up but; it reached significant trend on 1st, 3rd day
and at 3 months postoperatively. Also, a significant increase in
C/D ratios was observed in recipients receiving graft with TT and
CT genotypes compared to recipients receiving graft with CC geno-
type late at 3 and 6 months postoperatively; meanwhile no signif-
icant difference was observed during the remaining period of the
study (Table 3).
To show the impact of the graft with different ABCB1 and
CYP3A5 genotypes on the recipients TAC pharmacokinetic activity:
The patients were divided into 4 groups regarding each gene:
CYP3A5 Group I: recipients carrying CYP3A5 ⁄1 allele (expres-
sers) receiving graft with CYP3A5 ⁄1 allele; ⁄1/⁄1, n = 22) (refer-
ence group a)
CYP3A5 Group II: recipients carrying CYP3A5 ⁄1 allele (expres-
sers) receiving graft with CYP3A5 ⁄3⁄/3 non expresser genotype;
⁄1/3⁄3, n = 8)
CYP3A5 Group III: CYP3A5 ⁄3⁄/3 non expresser genotype carry-
ing recipients receiving graft with CYP3A5 ⁄3/⁄3 genotype;
3⁄3/3⁄3, n = 12) (reference group b)Table 2
Tacrolimus C/D post-transplant according to donors’ and recipients’ CYP3A5 genotype.
C/D ratios (ng/ml)/(mg/
kg/day)
Recipient Genotype
⁄1/⁄1 and ⁄1/⁄3 (n = 30)
Mean ± SD
⁄3/⁄3 (n = 18)
Mean ± SD
Day 1 49.7 ± 20.5 82.4 ± 46.2
Day 2 60.6 ± 21.4 96.7 ± 37.6
Day 3 64.0 ± 25.5 92.4 ± 52.2
Week 1 45.8 ± 70.0 97.9 ± 12.13
Week 2 78.08 ± 43.7 156.3 ± 119.3
Month 1 74.4 ± 29.0 82.7 ± 34.12
Month 3 117.6 ± 43.1 96.7 ± 22.6
Month 6 92.7 ± 47.9 89.7 ± 19.4
SD = standard deviation, C/D = concentration/dose, p value < 0.05 = significant⁄, the used
Please cite this article in press as: Helal M et al. Egypt J Med Hum Genet (201CYP3A5 Group IV: CYP3A5 ⁄3/⁄3 non expresser genotype carry-
ing recipients receiving graft with CYP3A5 ⁄1 allele (expres-
sers); 3⁄3/⁄1, n = 6)
Where it was noticed that TAC doses were higher in recipients
carrying ⁄1 allele of CYP3A5 gene receiving graft from donors with
⁄1 allele of CYP3A5 gene (group I) compared to recipients carrying
⁄1 allele receiving graft from donors with ⁄3⁄3 genotype (group II)
with significant difference during 1st month. No significant differ-
ence was observed in TAC doses between recipients carrying ⁄3/⁄3
genotype receiving graft from donors with ⁄3/⁄3 genotype (group
III) compared to recipients carrying ⁄3/⁄3 genotype receiving graft
from donors with ⁄1 allele (group IV). A significant decrease was
found in TAC C/D ratio at 3rd day and 6th month in recipients car-
rying ⁄1 allele receiving graft from ⁄1 allele (group I) compared to
recipients carrying ⁄1 allele receiving graft from donors with ⁄3⁄/3
genotype (group II). While TAC C/D ratios were higher in recipients
carrying ⁄3/⁄3 genotype receiving grafts from donors carrying ⁄3/⁄3
genotype (group III) compared to recipients carrying ⁄3/⁄3 geno-
type receiving grafts from donors with ⁄1 allele of CYP3A5 gene
(group IV) with significant difference at 1 and 6 months (Table 4).
ABCB1 Group I: recipients with ABCB1 CC genotype (high activ-
ity) receiving graft with ABCB1 CC genotype, CC/CC, n = 12 (ref-
erence group a)
ABCB1 Group II: recipients with ABCB1 CC genotype (high activ-
ity) receiving graft with ABCB1 T allele (low activity), CC/T,
n = 10
ABCB1 Group III: ABCB1 T allele carrying recipients (low activ-
ity) receiving graft with ABCB1 T allele, CT or TT/CT or TT,
n = 16) (reference group b)
ABCB1 Group IV: ABCB1T allele carrying recipients (low activ-
ity) receiving graft with ABCB1 CC genotype (high activity), CT
or TT/CC, n = 10).
TAC dose was higher in recipients with CC genotype (high activ-
ity) receiving graft from donors with CC genotype (group I) com-
pared to recipients carrying CC genotype receiving graft from
donors with T allele (group II) with significant difference during
1st month (early postoperatively) and at 3, 6 months postopera-
tively. There was no significant difference in TAC concentration
between recipients with CC (high activity) genotype receiving graft
from donors carrying CC genotype compared to recipients carrying
CC genotype receiving graft from donors with T allele during the
study period. There was no significant difference in TAC C/D ratios
between recipients with CC (high activity) genotype receiving graft
from donors with CC genotype (group I) compared to recipients
carrying CC genotype receiving graft from donors with T allele
(group II) except at 6 months where there was significant increase
in C/D ratio in recipients with CC genotype receiving graft from
donors with T allele (group II). There was no significant differenceP
value
Donor Genotype P
value⁄1/⁄1 and ⁄1/⁄3 (n = 28)
Mean ± SD
⁄3/⁄3 (n = 20)
Mean ± SD
0.036⁄ 59.5 ± 26.1 62.3 ± 40.4 0.76
0.002⁄ 70.7 ± 25.6 77.1 ± 38.4 0.47
0.09 73.9 ± 20.8 76.8 ± 50.7 0.81
0.186 49.0 ± 14.6 100.5 ± 72.0 0.004⁄
0.001⁄ 101.9 ± 33.2 109.15 ± 109.9 0.70
0.09 75.0 ± 23.4 88.3 ± 39.5 0.15
0.05 101.0 ± 33.2 116.0 ± 40.4 0.16
0.813 83.1 ± 22.3 98.2 ± 49.1 0.15
test: Mann-Whitney Test.
6), http://dx.doi.org/10.1016/j.ejmhg.2016.10.005
Table 3
Tacrolimus C/D post-transplant according to donors’ and recipients’ ABCB1 genotype.
C/D ratios (ng/ml)/(mg/kg/day) Recipients Genotype P value Donors Genotype P value
CC (n = 22) Mean ± SD CT and TT(n = 26) Mean ± SD CC (n = 22) Mean ± SD Ct and TT (n = 26)Mean ± SD
Day 1 45.18 ± 24.83 71.88 ± 37.27 0.02⁄ 62.7 ± 39.1 70.7 ± 29.4 0.41
Day 2 77.69 ± 20.02 82.01 ± 39.10 0.19 69.3 ± 41.6 79.0 ± 23.7 0.07
Day 3 46.28 ± 16.68 97.42 ± 38.98 <0.001⁄ 72.1 ± 50.8 77.6 ± 30.7 0.11
Week 1 95.04 ± 73.38 105.57 ± 49.16 0.13 100.7 ± 76.5 98.2 ± 45.4 0.59
Week 2 96.0 ± 48.42 114.34 ± 108.67 0.88 90.3 ± 43.0 126.6 ± 120.7 0.63
Month 1 80.72 ± 34.72 84.53 ± 34.90 0.71 84.9 ± 30.5 81.0 ± 37.4 0.43
Month 3 95.47 ± 41.83 121.96 ± 30.12 0.009⁄ 97.0 ± 31.8 120.7 ± 39.9 0.02⁄
Month 6 88.30 ± 46.78 94.78 ± 33.66 0.60 73.5 ± 29.4 105.7 ± 42.1 0.01⁄
SD = standard deviation, C/D = concentration/dose, p value < 0.05 = significant⁄, the used test: Mann-Whitney test.
Table 4
Tacrolimus blood C/D ratio (ng/ml) / (mg/kg/day) post-transplantation in different groups of combined CYP3A5 genotypes in both donors and recipients.
C/D ratios (ng/ml)/
(mg/kg/day)
Genotype P
value
Genotype P
value
Group I ⁄1/⁄1 and ⁄1/⁄3/⁄1/⁄1 and
⁄1/⁄3 (n = 22) Mean ± SD
Group II ⁄1/⁄1 and ⁄1/⁄3/⁄3/⁄3
(n = 8) Mean ± SD
Group III ⁄3/⁄3/⁄3/⁄3
(n = 12) Mean ± SD
Group IV ⁄3/⁄3/1/⁄1 and ⁄1/⁄3
(n = 6) Mean ± SD
Day 1 49.7 ± 20.5 49.7 ± 21.9 0.824 99.9 ± 61.8 69.2 ± 27.7 0.298
Day 2 54.3 ± 23.9 63.4 ± 20.3 0.373 118.1 ± 52.1 83.9 ± 19.1 0.127
Day 3 58.7 ± 28.1 77.4 ± 8.8 0.042⁄ 124.5 ± 76.7 76.4 ± 26.4 0.259
Week 1 68.5 ± 29.5 108.7 ± 77.5 0.347 122.6 ± 36.4 70.6 ± 36.6 0.060
Week 2 73.5 ± 27.3 79.6 ± 48.4 0.727 120.8 ± 21.2 227.3 ± 195.9 0.259
Month 1 67.1 ± 22.3 77.1 ± 31.1 0.452 129.3 ± 42.5 80.2 ± 23.6 0.024⁄
Month 3 115.6 ± 41.9 118.4 ± 44.5 0.851 91.2 ± 23.1 107.5 ± 19.1 0.259
Month 6 81.4 ± 27.3 106.8 ± 21.4 0.029⁄ 105.9 ± 3.7 84.3 ± 19.6 0.045⁄
SD = standard deviation, C/D = concentration/dose, p value < 0.05 = significant⁄, the used test: MannWhitney test.
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gene receiving graft from donors with T allele (group III) compared
to recipients carrying T allele receiving graft from donors with CC
(high activity) genotype (group IV) except at 6 months (late post-
operatively) where recipients with T allele receiving graft from
donors with T allele had significant increase in C/D ratio (Table 5).4. Discussion
The haplotype distribution of ABCB1 gene in the present study
showed that C allele was 62.5% while T allele was 37.5%. Different
alleles of ABCB1 gene did not show significant difference between
donors and recipients. These frequencies were similar to that of
other Caucasian populations (T allele frequency was 40–50%)
[14], and different from that documented in Africans and African
Americans (T allele frequency was 0.9–13%) [15], and in European
Americans (T allele frequency was 62%), Asian Americans (T allele
frequency was 27%) and Mexican Americans (T allele frequency
was 35%) [16]. In other ethnic groups, like the Africans and African
American populations, a lower T frequency has been reported [17].Table 5
Tacrolimus blood C/D ratio (ng/ml)/(mg/kg/day) post-transplantation in different groups o
C/D ratios (ng/ml)/
(mg/kg/day)
Genotype P
val
Group I CC/CC (n = 12)
Mean ± SD
Group II CC/CT and TT
(n = 10) Mean ± SD
Day 1 36.2 ± 20.7 59.9 ± 25.5 0.0
Day 2 57.12 ± 23.61 71.9 ± 10.8 0.2
Day 3 39.09 ± 6.7 53.4 ± 20.6 0.0
Week 1 75.46 ± 21.9 111.3 ± 96.1 0.7
Week 2 89.4 ± 32.7 101.4 ± 59.4 1.0
Month 1 77.1 ± 28.6 83.7 ± 40.1 0.7
Month 3 84.4 ± 25.5 108.7 ± 54.1 0.2
Month 6 69.7 ± 37.09 110.5 ± 49.13 0.0
SD = standard deviation, C/D = concentration/dose, p value < 0.05 = significant⁄, the used
Please cite this article in press as: Helal M et al. Egypt J Med Hum Genet (201In the present study the ABCB1 genotypes of the 48 liver trans-
planted recipients and their donors, were 22 CC (45.9%), 16 CT
(33.3%) and 10 TT (20.8%).
Provenzani et al. [18], stated that the CC, CT and TT genotypes in
recipients were 9 (17.7%), 26 (51%) and 16 (31.3%) cases, respec-
tively. Among the donors, the C/C, C/T and T/T genotypes were
observed in 12 (23.5%), 26 (51%) and 13 (25.5%) cases, respectively.
In the current study, recipients own ABCB1 gene polymorphism
affected the TAC daily dose, concentration and C/D ratio during and
after the first month early postoperatively. TAC daily dose was sig-
nificantly increased among recipients carrying CC genotypes with
high activity compared to recipients carrying CT and TT genotypes.
Where CC genotype carrying recipients needed higher doses to
reach the desired concentration early postoperatively (till the
beginning of the third month).
A significant decrease of TAC concentration was observed on the
third day, first and second weeks postoperatively, in recipients car-
rying CC genotype (high activity) compared to those carrying CT
and TT genotypes, which indicates that T carrying alleles recipients
reached trough concentration faster than CC recipients in the first
two weeks post operatively.f combined ABCB1 genotypes in both donors and recipients.
ue
Genotype P
value
Group III CT and TT/CT and
(n = 16) Mean ± SD
Group IV CT and TT/CC
(n = 10) Mean ± SD
50 75.2 ± 30.6 67.1 ± 46.3 0.197
84 83.1 ± 28.1 81.5 ± 52.5 0.411
95 105.0 ± 54.6 92.6 ± 26.0 0.833
91 112.4 ± 50.8 94.5 ± 46.7 0.205
0 156.8 ± 166.8 90.7 ± 48.6 0.773
91 86.4 ± 13.9 83.5 ± 42.7 0.291
90 128.1 ± 27.3 112.0 ± 33.1 0.205
34⁄ 102.6 ± 38.49 79.0 ± 11.1 0.045⁄
test: Mann-Whitney U Test.
6), http://dx.doi.org/10.1016/j.ejmhg.2016.10.005
6 M. Helal et al. / The Egyptian Journal of Medical Human Genetics xxx (2016) xxx–xxxSignificant decrease in C/D ratio was detected among recipients
carrying CC genotype (high activity) compared to those carrying CT
and TT genotypes early in first and third days post transplantation
and after 3 months of follow up which agreed with Liu et al. [19]
and Vavadari et al. [20]. However, Shi et al. [21], reported no signif-
icant association between ABCB1 polymorphism and TAC
pharmacokinetics.
Sakaeda et al. [22], reported that subjects homozygous for the
exon 26 3435T variant present a 2-fold reduction of intestinal P-
gp, which might influence the TAC bioavailability. Also, Wei-Lin
et al. [12], stated that patients with no sequence variant in the
exon 26 of the ABCB1 gene are more likely to extrude tacrolimus
from enterocytes and therefore need a higher daily dose to achieve
adequate blood tacrolimus levels which confirmed the results of
the current study.
In an attempt to discover the effect of the donors graft with dif-
ferent ABCB1 genotypes on the recipients’ pharmacokinetic activ-
ity, recipients were divided into two groups, one with high
activity CC genotype and the other with the low activity T allele
carrying genotypes. The two groups were further subdivided,
where the recipients with the high activity CC genotypes were split
up to two groups, the first received a graft with CC genotype
homogenous with recipient and the second received T allele carry-
ing graft. Also, recipients with low activity T allele genotypes were
split up to two groups, the first received T allele carrying graft
homogenous with recipient and the other group took graft with
CC genotype.
In this study, the analysis of recipients’ and donors’ ABCB1
genotypes, revealed that, the weight adjusted doses of TAC were
higher in recipients carrying CC genotype of ABCB1 gene and
receiving livers from the same genotype compared to those receiv-
ing livers with the T allele of ABCB1 during period of the study with
significant increase early postoperatively (1st month) (P = 0.008)
and late after 3, 6 months postoperatively (P = 0.024, 0.049 respec-
tively). While recipients carrying T allele and receiving graft from
CC genotype donors needed higher TAC doses compared to those
receiving T allele grafts late postoperatively at 6 months when
the graft became fully functioning. There was no effect of the graft
ABCB1 genotype regarding the TAC blood concentration regardless
of the recipients’ genotype. The ABCB1 genotype of the graft
affected TAC C/D ratios at 6 months postoperatively where lower
C/D was detected in grafts carrying the CC genotype compared to
grafts with T allele regardless of the recipients’ ABCB1 genotype
as the transplanted liver became fully functioning. These results
matched previous results given by Tada et al. [23] and Wei-Lin
et al. [12]. These data suggest that ABCB1 polymorphism may be
important in liver transplant patients due to their effects on TAC
levels in the liver, which might be a good marker to predict the
liver graft rejection [24].
In the current study, the haplotype distribution of CYP3A5 gene
in the present study showed that ⁄1 allele was 41.7% while ⁄3 allele
was 58.3%. Genotypes (⁄1/⁄1), (⁄1/⁄3) and (⁄3/⁄3) of CYP3A5 gene
were observed in 20.8%, 41.7% and 37.5% of recipients respectively,
while donors showed 20.8%, 37.5% and 41.7% respectively. No sig-
nificant difference between recipients and donors groups was
detected.
Different frequencies were reported by Provenzani et al. [18],
who found that CYP3A5⁄3/⁄3 genotype was observed in (86.3%)
recipient, CYP3A5⁄1/⁄3 in (11.7%) and CYP3A5⁄1/⁄1 in (2%). For
the corresponding donors, CYP3A5⁄3/⁄3 was present in (78.4%),
CYP3A5⁄1/⁄3 in 10 (19.6%) and CYP3A5⁄1/⁄1 in (2%).
Differences of genotypes distribution may be attributed to dif-
ferent ethnic groups of the various studies. Where Lamba et al.
[25], stated that 90% of Caucasian subjects are homozygous for
the non-functional variant CYP3A5⁄3, the percentage of
CYP3A5⁄3/⁄3 subjects was 84.9% and the total frequency of thePlease cite this article in press as: Helal M et al. Egypt J Med Hum Genet (201variant ⁄3 was 91.7%. The percentage of CYP3A5⁄3/⁄3 subjects is
lower (20–30%) in other ethnic groups, in particular among Afri-
cans and African Americans.
It was confirmed that for tacrolimus that reached the liver, the
CYP3A5 polymorphism became the key factor. The deficient func-
tion of P-450 decoded by CYP3A5⁄3/⁄3 genotype made the intra-
hepatic metabolism efficacy much lower, as it kept the serum
tacrolimus concentration at stable targeted levels [12].
In this view, this study showed that there was no effect of the
recipients own CYP3A5 polymorphism on mean weight adjusted
TAC dose. However, there was a significant increase in TAC blood
concentration in the non-expressers ⁄3/⁄3 genotype who reached
the desired blood trough concentration faster during the first two
weeks postoperatively, compared to recipients with at least one
copy of T allele (⁄1/⁄1 and ⁄1/⁄3) genotypes who considered to
express the functioning enzyme, this significant difference was
not observed during 1, 3 and 6 months postoperatively. Also, a sig-
nificant increase was observed in C/D ratio among recipients carry-
ing ⁄3/⁄3 genotype compared with recipients carrying ⁄1/⁄1 and
⁄1/⁄3 genotypes during the first 2 days and at 2 weeks postopera-
tively, meanwhile no significant difference was observed during
the remaining period of the follow up. This may be because in early
stages after operation, the conditions of the recipients were not
stable, and liver and intestine dysfunction resulting from ischemia
reperfusion injury had not recovered [26].
Similar results were given by Gómez-Bravo et al. [27] and Buen-
dia et al. [28]. Another study conducted by De Wildt et al. [29] did
not identify any relationship between recipient CYP3A5 genotype
and TAC dosing, they supposed that the main reason for this lack
of association was probably that variations in TAC deposit are lar-
gely dependent on hepatic metabolism and to a lesser extent on
intestinal metabolism in the first 14 days after transplantation.
Goto et al. [30] and Day et al. [31] demonstrated that in liver
transplant recipients, patients who do not express functional
CYP3A5 (individuals homozygous for CYP3A5⁄3, require signifi-
cantly less TAC to reach target concentrations compared to
patients who do express CYP3A5 (CYP3A5⁄1 allele carriers, requir-
ing 30–50% higher TAC doses).
Also, Wu et al. [32], stated that individuals with functional poly-
morphism CYP3A5⁄3, the 3⁄3⁄ genotype showed less efficient
metabolism of TAC compared with those displaying a wild-type
genotype. CYP3A5 ⁄3/⁄3 genotype displayed sequence variability
in intron 3 that caused a cryptic splice site and transcribed an
extraordinarily spliced mRNA, and the truncated protein resulted
in the absence of normal CYP3A5 protein from tissue.
These results support a possible benefit of a pharmacogenetic
dosing strategy, implying the administration of higher TAC initial
doses to CYP3A5 expressers to achieve the targeted concentrations
more rapidly. This would be promising as achieving optimal drug
exposure in the first days after transplantation is important as this
is the period with the highest risk of acute rejection [33,24].
Because most CYP3A5 enzymes are enriched in the intestinal
tract and liver, the contribution of the donor liver should be con-
sidered when examining the individual variations of tacrolimus
pharmacokinetics. In addition, the first-pass elimination of
immune suppressants in the gut is thought to account in part for
individual variations [34].
In an attempt to find the impact of the donors’ graft with differ-
ent CYP3A5 genotypes on the recipients’ pharmacokinetic activity,
recipients were divided into two groups, one expresser of protein
carrying the ⁄1 allele genotypes and the other with the non-
expresser ⁄3⁄3 genotype. The two groups were further subdivided,
where the ⁄1 allele carrying recipients (expressers) were split up to
two groups, the first received a graft with ⁄1 allele genotypes
homogenous with the recipient and the second received ⁄3⁄3 geno-
type graft. Also, recipients with ⁄3⁄3 genotype were split up to two6), http://dx.doi.org/10.1016/j.ejmhg.2016.10.005
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with recipient and the other group took graft with ⁄1 allele
genotypes.
In this study, the analysis of recipients’ and donors’ CYP3A5
genotypes, revealed that, the weight adjusted doses of TAC were
higher in recipients carrying ⁄1 allele genotypes of CYPA5 gene
and receiving livers carrying the same genotypes compared to
those receiving livers with the ⁄3/⁄3 genotype early postoperatively
during the 1st month.
There was no effect of the graft CYP3A5 genotype regarding TAC
blood concentration. Recipients carrying ⁄3/⁄3 genotype (non-
expresser) engrafted with CYP3A5 expressers (⁄1/⁄1 and ⁄1/⁄3)
achieved lower mean C/D ratio than those with grafts from non-
expressers (3⁄/3⁄) at the first month. Also, recipients engrafted
with 3⁄/3⁄ genotype had higher C/D at six months regardless of
the recipients CYPA5 genotype. These results agreed with other
study by Wang et al. [26] who found that higher tacrolimus C/D
ratios were detected in CYP3A5 non-expressers in both donors
and recipients and concluded that, only the CYP3A5⁄3/⁄3 genotype
recipients with CYP3A5⁄3/⁄3 liver required lower tacrolimus
dosage to achieve the target trough concentration.
Buendía et al. [35] found that, dose-adjusted TAC trough con-
centrations were significantly lower in those in whom the donor
or recipient expressed ⁄1 allele compared with those in whom nei-
ther the donor nor recipient expressed this allele at 7 days and 2, 3,
6, and 12 months after transplant. Argudo et al. [36] stated that,
from the first month after transplantation, patients with grafts
from donor carriers of allele⁄1 had lower concentration-dose ratios
compared with patients with grafts from donor non-carriers of that
allele. The recipient’s genotype for CYP3A5⁄1/⁄3-polymorphism
had no influence on TAC pharmacokinetics, with no differences
between carriers and non-carriers of allele⁄1.
Tacrolimus pharmacokinetics was influenced by the recipients
and donors genotypes which could be explained as, Wei-Lin et al.
[12] stated that in the first month after transplantation, early post
operatively before the transplanted liver takes over its full func-
tion, the absorption functioned before the metabolism started,
and P-gp acted as the first clearance effect to tacrolimus, which
reduced the serum volume of the drug in vivo, meanwhile later
it confirmed that for tacrolimus that reached the liver, the CYP3A5
polymorphism became the key factor. The deficient function of P-
450 decoded by CYP3A5⁄3/⁄3 genotype made the intrahepatic
metabolism efficacy much lower, as it kept the serum tacrolimus
concentration at stable targeted levels.
Also, Uesugi et al. [37] and Provenzani et al. [18], proposed that
in liver transplant patients, TAC doses needed to reach the target
trough blood levels may increase along time. This might be due
to the fact that, early after transplantation, the engrafted liver can-
not fully perform its metabolic function owing to the damage asso-
ciated with ischemia and hepatic reperfusion.5. Conclusion
This study has demonstrated the high variability of the tacroli-
mus doses required to maintain the desired drug levels. Recipients’
ABCB1 genotypes affected the dose requirements and drug blood
concentration as well as C/D ratio mainly in the first 3 months post
operatively, while the grafts’ ABCB1 genotypes mostly affected the
drug C/D ratio late mainly at six months postoperatively. Recipi-
ents CYP3A5 genotypes affected the drug pharmacokinetics mainly
in the first two weeks after transplantation, while the grafts’
CYP3A5 genotypes affected the drug C/D ratio late mainly at six
months postoperatively after the grafted liver became fully
functioning.Please cite this article in press as: Helal M et al. Egypt J Med Hum Genet (201Over all in the early postoperative period, in Egyptian liver
transplantation patients, the recipients’ genetics had a greater
impact rather than the donors’ genetics on the tacrolimus pharma-
cokinetics. In the late postoperative period the donors’ genetics,
rather than that of the recipients’, had a more important effect
on tacrolimus pharmacokinetics. Thus screening to detect single
nucleotide polymorphisms of the above genes prior to transplanta-
tion might be helpful for tailoring the appropriate drug regimen for
each patient to achieve the desired immunosuppression with min-
imal side effects.Declaration of conflict of interest
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